Since 2013, the price of an anti-cancer drug that has been on the U.S. market for 40 years and whose patent protection has expired has risen by 1,400%, making it unaffordable for some patients who rely on it to extend their lives.
This is lomustine, which was launched in 1976 to treat brain tumors and Hodgkin lymphoma. As this anti-cancer drug faces no competition from generics, its distributor, NextSource Biotechnology LLC, possesses significant pricing power.
The U.S. Food and Drug Administration (FDA) is seeking to introduce more competition for drugs like lomustine. According to a list released by the agency earlier this month, there are currently at least 319 drugs in the U.S. with expired patents that have no generic versions on the market.
The FDA stated that it will expedite the approval process for generic applications for drugs on this list to lower drug prices.
At the Worldway Wealth Club, we are committed to enriching your global financial investment perspective and advocating for a high-end, international lifestyle. With twenty years of professional experience in top-tier asset allocation, we strive to create an international-quality elite business exchange circle for you, the pinnacle of society. For details, please call: 400-186-0266
